Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.

di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.